-+ 0.00%
-+ 0.00%
-+ 0.00%

BELITE BIO's pre-market share price fell 10.6% as the US Food and Drug Administration extended its review of eye medication.

Zhitongcaijing·11/20/2026 13:17:12
Listen to the news
BELITE BIO's pre-market share price fell 10.6% as the US Food and Drug Administration extended its review of eye medication.